BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10597732)

  • 1. Drug development in prostate cancer.
    Ripple GH; Wilding G
    Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).
    Papatsoris AG; Karamouzis MV; Papavassiliou AG
    Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel molecular targets for prostate cancer therapy.
    Kamradt JM; Pienta KJ
    Semin Oncol; 1999 Apr; 26(2):234-43. PubMed ID: 10597734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents for prostate cancer.
    Reese DM
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):547-57. PubMed ID: 11525296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
    Liu G; Gandara DR; Lara PN; Raghavan D; Doroshow JH; Twardowski P; Kantoff P; Oh W; Kim K; Wilding G
    Clin Cancer Res; 2004 Feb; 10(3):924-8. PubMed ID: 14871968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors in the treatment of prostate cancer.
    Kluetz PG; Figg WD; Dahut WL
    Expert Opin Pharmacother; 2010 Feb; 11(2):233-47. PubMed ID: 20088745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
    Senderowicz AM
    Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
    McCarty MF
    Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets of selenium in prostate cancer prevention (Review).
    Abdulah R; Kobayashi K; Yamazaki C; Koyama H
    Int J Oncol; 2011 Aug; 39(2):301-9. PubMed ID: 21567081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol.
    Ariazi EA; Satomi Y; Ellis MJ; Haag JD; Shi W; Sattler CA; Gould MN
    Cancer Res; 1999 Apr; 59(8):1917-28. PubMed ID: 10213501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.